Anti-Human CD34 (HB-34a) – Biotin

Product No.: C945

- -
- -
Clone
HB-34a
Target
CD34
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Gp105-120, My10, mucosialin
Isotype
Mouse IgG1 κ
Applications
FC

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Immunogen
Human endothelial vesicles
Product Concentration
0.5 mg/ml
Formulation
This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
State of Matter
Liquid
Storage and Handling
This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2-8°C Wet Ice
Additional Applications Reported In Literature ?
FC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
HB-34a activity is directed against human CD34.
Background
CD34 is a transmembrane phosphoglycoprotein that contains a heavily sialylated extracellular domain, O- and N-linked glycosylation sites, a single transmembrane helix, and a cytoplasmic tail that contains PDZ-domain binding motifs 1. CD34 interacts with L-selectin (CD62L), CrkL 1, and integrin 2 and also exerts a synergistic effect with inflammatory cytokines and chemokines 2. CD34 functions in cell adhesion, regulation of cell differentiation and proliferation, trafficking of hematopoietic stem cells to niches within the bone marrow 1, adult angiogenesis 3, inflammatory cell chemotaxis, and enhancement of the inflammatory response 2. Additionally, CD34 is involved in cell migration, via the recruitment of lymphocytes to specialized high endothelial venules that line the secondary lymphoid organs, as well as T cell homing to these lymphoid organs 4.

CD34 is routinely used in clinical settings to identify and isolate hematopoietic stem and progenitor cells for bone marrow transplants to ensure rapid engraftment 1, for example during hematopoietic reconstitution after myeloablative therapy in cancer patients 4. CD34+ autologous stem cells are also used as a novel therapeutic for ischemia with non-obstructive coronary arteries with coronary microvascular dysfunction 3. Clinical trials have investigated the use of CD34+ stem cell therapy in peripheral ischemia, nonischemic cardiomyopathy, myocardial infarction, ischemic stroke, and refractory angina. Additionally, CD34 expression is abnormally high in the intestine of inflammatory bowel disease (IBD) patients and is involved in the occurrence and development of IBD via its interactions with adhesion molecules as well as playing a role in the migration of immune cells to the inflammatory site 2.
Antigen Distribution
CD34 is a general marker of progenitor cells. CD34 is expressed on hematopoietic stem and progenitor cells as well as nonhematopoietic cell types including vascular endothelial progenitors, fibrocytes, mesenchymal stromal cells, interstitial cells, epithelial progenitors, muscle satellite cells, corneal keratocytes, vascular endothelial progenitors, mucosal dendritic cells, mast cells, and eosinophils.
Ligand/Receptor
L-selectin, E-selectin
NCBI Gene Bank ID
UniProt.org
Research Area
Cell Adhesion
.
Cell Biology
.
Immunology
.
Neuroscience
.
Stem Cell

References & Citations

1. Sidney LE, Branch MJ, Dunphy SE, et al. Stem Cells. 32(6):1380-1389. 2014.
2. Li Z, Dong S, Huang S, et al. Front Physiol. 14:1144980. 2023.
3. Rai B, Shukla J, Henry TD, et al. Cells. 10(5):1137. 2021.
4. AbuSamra DB, Aleisa FA, Al-Amoodi AS, et al. Blood Adv. 1(27):2799-2816. 2017.
Flow Cytometry

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.